TAIJI GROUP(SH:600129) 光大证券研究·2026-03-14 00:06Group 1: Policy and Industry Development - The central government emphasizes the acceleration of traditional Chinese medicine (TCM) innovation and the quality upgrade of the Chinese medicine industry, aiming to build a health-oriented society by 2025 [4] - The Ministry of Industry and Information Technology and eight other ministries released a plan for high-quality development of the Chinese medicine industry from 2026 to 2030, focusing on enhancing the supply chain, digitalization, and green development [4] - The plan aims to cultivate leading enterprises in the TCM industry and establish high-standard raw material production bases, which will increase industry compliance and concentration, benefiting companies with strong quality control and R&D capabilities [4] Group 2: Company Strategy and Operations - The company is focusing on its core pharmaceutical business, divesting idle assets, and enhancing management efficiency by liquidating subsidiaries and transferring stakes [5] - The company aims to drive growth through "technology innovation" and "marketing innovation," strengthening its industrial marketing system and accelerating the development of major products and new drug innovations [5] - The company has announced a projected net profit of approximately 11 million yuan for 2025, representing a year-on-year increase of about 313%, with a non-recurring profit of around 6.2 million yuan due to asset disposals and government subsidies [6][7] Group 3: Performance Recovery - The company is experiencing a recovery in performance after facing adverse factors, with expectations of returning to a rapid growth trajectory [7] - Sales and revenue of major products have declined year-on-year due to policy impacts and inventory digestion, but the company is focusing on operational control and cost reduction to stabilize quality [6][7]